Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Exelixis's Total Assets for the quarter that ended in Jun. 2026 was €2,165 Mil.
During the past 12 months, Exelixis's average Total Assets Growth Rate was -12.30% per year.
During the past 3 years, the average Total Assets Growth Rate was 0.40% per year.
During the past 5 years, the average Total Assets Growth Rate was 14.60% per year.
During the past 10 years, the average Total Assets Growth Rate was 30.30% per year.
During the past 13 years, Exelixis's highest 3-Year average Total Assets Growth Rate was 136.60%. The lowest was -18.90%. And the median was 14.30%.
Total Assets is connected with ROA %. Exelixis's annualizedROA % for the quarter that ended in Jun. 2026 was 33.40%. Total Assets is also linked to Revenue through Asset Turnover. Exelixis's Asset Turnover for the quarter that ended in Jun. 2026 was 0.25.
Note:
The Net Income data used here is four times the quarterly (Jun. 2026) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Exelixis's Asset Turnover for the quarter that ended in Jun. 2026 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Exelixis Total Assets Related Terms
Exelixis Total Assets Historical Data
* Premium members only.
The historical data trend for Exelixis's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Exelixis's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Exelixis (FRA:EX9) has a Total Assets of €2,165 Mil as of Jun. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Exelixis and its competitors.
Is Exelixis' Total Assets too high?
Exelixis' current Total Assets is €2,165 Mil. Overall, Exelixis has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Exelixis' Total Assets compare to MDGL and AXSM?
Exelixis' Total Assets of €2,165 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Exelixis and its competitors. Exelixis's current Total Assets is €2,165 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exelixis stock overvalued right now?
Based on GuruFocus' analysis, Exelixis (FRA:EX9) is currently considered Modestly Overvalued. The stock's GF Value™ is €40.66, compared to a current price of €46.16 — trading 13.5% above its estimated fair value. The current Total Assets is €2,165 Mil. Exelixis' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Exelixis (FRA:EX9), the current Total Assets is €2,165 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Exelixis (FRA:EX9) Overvalued in 2026?
Based on GuruFocus' analysis, Exelixis stock appears to be overvalued.
The current stock price of €46.16 is trading 13.5% above its estimated GF Value™ of €40.66.
GuruFocus considers Exelixis to be Modestly Overvalued.
Key valuation signals for FRA:EX9:
Total Assets: €2,165 Mil
GF Value™: €40.66 vs. price of €46.16 (13.5% above fair value)
No single metric tells the full story. See the FRA:EX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
90GF Score
Get the complete analysis for FRA:EX9
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:EX9 has been successfully added to your 
